Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alireza Atri

Showing results (51-60 of 143) with videos related to

Pageof 15
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|April 14, 2025
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?Krista Lanctot, Linus Jönsson, Alireza Atri, et al.
JAMA|January 11, 2018
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical TrialsAlireza Atri, Lutz Frölich, Clive Ballard, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Journal of Alzheimer'S Disease : JAD|January 15, 2019
Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's DiseaseLutz Frölich, Alireza Atri, Clive Ballard, et al.
Frontiers in Neuroscience|July 4, 2017
Inter-Rater Reliability of Preprocessing EEG Data: Impact of Subjective Artifact Removal on Associative Memory Task ERP ResultsSteven D Shirk, Donald G McLaren, Jessica S Bloomfield, et al.
Alzheimer'S Research & Therapy|February 29, 2024
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's diseaseLinus Jönsson, Milana Ivkovic, Alireza Atri, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsSydney Y Schaefer, Michael H Malek-Ahmadi, Angela Kuramoto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty careBradford C Dickerson, Alireza Atri, Carolyn Clevenger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary careAlireza Atri, Bradford C Dickerson, Carolyn Clevenger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instrumentsAlireza Atri, Bradford C Dickerson, Carolyn Clevenger, et al.
Pageof 15

Showing results (51-60 of 143) with videos related to

Sort By:
Pageof 15
Alzheimer'S & Dementia (New York, N. Y.)|April 14, 2025
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?Krista Lanctot, Linus Jönsson, Alireza Atri, et al.
JAMA|January 11, 2018
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical TrialsAlireza Atri, Lutz Frölich, Clive Ballard, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Journal of Alzheimer'S Disease : JAD|January 15, 2019
Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's DiseaseLutz Frölich, Alireza Atri, Clive Ballard, et al.
Frontiers in Neuroscience|July 4, 2017
Inter-Rater Reliability of Preprocessing EEG Data: Impact of Subjective Artifact Removal on Associative Memory Task ERP ResultsSteven D Shirk, Donald G McLaren, Jessica S Bloomfield, et al.
Alzheimer'S Research & Therapy|February 29, 2024
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's diseaseLinus Jönsson, Milana Ivkovic, Alireza Atri, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsSydney Y Schaefer, Michael H Malek-Ahmadi, Angela Kuramoto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty careBradford C Dickerson, Alireza Atri, Carolyn Clevenger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary careAlireza Atri, Bradford C Dickerson, Carolyn Clevenger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instrumentsAlireza Atri, Bradford C Dickerson, Carolyn Clevenger, et al.
Pageof 15